Hesperidin Side Effects

Reported Hesperidin side effects

Hesperidin has one of the best safety profiles of any polyphenol supplement on BodyHackGuide, with decades of prescription-grade use in European phlebology producing no ceiling-dose toxicity, no meaningful drug interactions at typical doses, and no teratogenic signals at dietary intakes. The most commonly reported side effects in clinical trials of MPFF (1000 mg/day) and 2S-hesperidin (500–900 mg/day) are mild and GI-predominant: occasional dyspepsia, nausea, loose stools, and flatulence, each reported in <5% of participants and generally indistinguishable from placebo rates. Allergic reactions to hesperidin supplements are very rare but do occur, usually as skin rash or urticaria. People with documented citrus allergies should be cautious about high-dose hesperidin supplementation, though the hesperidin molecule itself is not a common allergen — most citrus allergies are driven by LTPs (lipid transfer proteins) or profilins, not flavonoids. If you develop a rash after starting a hesperidin supplement, discontinue and consider an alternative flavonoid. Bleeding and anticoagulation: at typical supplemental doses (500–1000 mg/day), hesperidin has minimal platelet-inhibitory activity and the clinical bleeding signal is essentially zero in the phlebology literature. At very high intakes (>2 g/day), or when combined with aspirin, fish oil, other anti-platelet agents, or warfarin, there is a theoretical additive bleeding risk. If you take warfarin, discuss any new polyphenol supplement with your anticoagulation clinic and check INR 2–3 weeks after starting. People on DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) do not need INR monitoring but should still mention the supplement to their prescriber. Pregnancy and lactation: dietary intake of citrus fruit and juice during pregnancy is universally considered safe and probably beneficial. Supplemental hesperidin at pharmacologic doses during pregnancy has not been formally studied and should be discussed with an obstetrician — MPFF is commonly prescribed in European phlebology for pregnancy-related varicose veins and lower-limb edema, with a long safety track record, though this is off-label in most of the world outside Europe. Dietary intake via citrus fruit is clearly fine; supplemental hesperidin at 500–1000 mg/day is probably fine but has not been systematically evaluated in pregnancy. Drug interactions: hesperidin does not meaningfully inhibit CYP3A4 at typical supplemental doses (the grapefruit-juice interaction that blocks CYP3A4 is driven by furanocoumarins like bergamottin and 6',7'-dihydroxybergamottin, not by hesperidin itself, and sweet oranges contain essentially no furanocoumarins). However, hesperidin has been shown to weakly inhibit P-glycoprotein and OATP1A2 in some preclinical studies, and at very high intakes this could theoretically increase absorption of P-gp and OATP substrates (fexofenadine, aliskiren, some statins). The clinical magnitude is probably minimal, but if you are on a narrow-therapeutic-index drug and take high-dose hesperidin, space the doses by 2–4 hours as a simple hedge. Orange juice itself can interact with several drugs via OATP1A2 inhibition (the so-called "orange juice effect" on fexofenadine), though this is a transient and dose-dependent effect. Kidney and liver: hesperidin has no known nephrotoxicity or hepatotoxicity at supplemental doses. The Daflon/MPFF safety database covers millions of patient-years at 1000 mg/day and has not produced a meaningful safety signal. Hesperidin is not on the HDS (herbal and dietary supplement) hepatotoxicity watchlist and does not show up in the LiverTox database as a concerning supplement, in contrast to EGCG at very high doses. Pediatric use: MPFF is used in European pediatric practice for chronic venous insufficiency and hemorrhoids with no meaningful safety signals, but pediatric supplementation should be supervised. Dietary citrus intake is obviously appropriate for children of any age who are not allergic. Rare adverse events worth noting: isolated case reports of headache, dizziness, and palpitations with MPFF, none rising above background rates. No signal for cardiac arrhythmia, QT prolongation, hepatic injury, renal injury, hematologic toxicity, or carcinogenicity in the published safety database.

When to continue, reduce, or stop Hesperidin

Hesperidin contraindications

Hesperidin is one of the safest polyphenol supplements in the BodyHackGuide catalog, and absolute contraindications are few. The main cautions: Citrus allergy. If you have a documented citrus allergy (orange, lemon, grapefruit, tangerine), skin-test a small dose first or avoid hesperidin supplements entirely. The hesperidin molecule is not a common allergen, but most commercial products are derived from orange peel and may contain trace amounts of allergenic citrus proteins. Active bleeding or bleeding disorders. At very high doses (>2 g/day) combined with aspirin, NSAIDs, warfarin, DOACs, or fish oil, hesperidin has a theoretical additive bleeding risk. If you have a bleeding disorder (hemophilia, von Willebrand disease, severe thrombocytopenia), active GI bleeding, or active hemorrhagic stroke, do not exceed dietary intake levels without hematology consultation. Note: the phlebology literature explicitly uses MPFF during acute hemorrhoidal bleeding, which is the opposite of the typical bleeding contraindication, so this caution is nuanced — the beneficial venotonic effect in hemorrhoids likely outweighs any small additive anti-platelet effect. Anticoagulation. If you take warfarin, adding or stopping hesperidin supplementation should prompt an INR check 2–3 weeks later. The interaction is probably minimal but worth monitoring. DOAC users do not need formal monitoring but should mention the supplement to their prescriber. Aspirin and NSAID users can take hesperidin without special monitoring at typical doses (500–1000 mg/day). Pregnancy and lactation. Dietary citrus intake is universally safe. Pharmacologic supplementation (500+ mg/day) has not been formally evaluated in pregnancy in the US/Canadian regulatory context, though MPFF is commonly prescribed in European phlebology for pregnancy-related varicose veins and lower-limb edema with a long safety record. Discuss with your obstetrician before starting supplemental hesperidin during pregnancy. Lactation: trace amounts of hesperidin appear in breast milk after citrus intake, with no documented harm to infants; supplemental hesperidin during lactation is probably fine but has not been systematically evaluated. Pediatric use. MPFF is used in European pediatric practice with no meaningful safety signal. In other regions, pediatric supplementation should be clinician-supervised. Dietary citrus intake is clearly appropriate for all non-allergic children. Liver and kidney disease. Hesperidin is not hepatotoxic or nephrotoxic at supplemental doses and is not a meaningful CYP450 inhibitor at typical doses. Patients with established liver or kidney disease do not have specific contraindications but should include hesperidin in their full medication and supplement review with their hepatologist or nephrologist. Drug interactions beyond anticoagulants. Hesperidin weakly inhibits P-glycoprotein and OATP1A2 in some preclinical models, which could theoretically increase blood levels of narrow-therapeutic-index drugs that are P-gp or OATP substrates (fexofenadine, aliskiren, digoxin, some statins). At typical supplemental doses the clinical magnitude is probably minimal, but if you take one of these drugs, take hesperidin at a different time of day (4+ hour gap) as a simple hedge. Orange juice interacts with fexofenadine and aliskiren via OATP1A2 inhibition and is a more clinically relevant interaction than hesperidin supplementation itself. Surgery. Stop high-dose hesperidin supplementation (>500 mg/day) 7 days before major surgery as a precaution against theoretical bleeding additivity, though the absolute risk is very low. MPFF for CVI is generally continued through elective surgery in European practice with no bleeding concerns noted in the surgical literature. Concurrent with aggressive platelet inhibition. For users on dual antiplatelet therapy (aspirin + clopidogrel, aspirin + ticagrelor) after stent placement or ACS, limit hesperidin to ≤500 mg/day and avoid concurrent high-dose fish oil unless specifically cleared by your cardiologist. Not contraindicated but commonly confused: Hesperidin is NOT the same as bergamot, bergapten, or bergamottin, even though these are all citrus-derived compounds. The grapefruit-juice interaction that affects CYP3A4-metabolized drugs is NOT driven by hesperidin but by furanocoumarins like bergamottin. Sweet oranges (the source of most commercial hesperidin) contain essentially no furanocoumarins, so hesperidin supplements do not carry the grapefruit-juice drug-interaction profile. However, bergamot-orange extract supplements DO contain bergamottin and DO interact with CYP3A4 substrates — read labels carefully. Red flags that warrant stopping hesperidin. Unexplained easy bruising or prolonged bleeding times, new or worsening allergic symptoms (rash, urticaria, angioedema), unexplained GI bleeding, or any worsening of the underlying venous or cardiovascular condition you are treating. In any of these scenarios, stop the supplement and consult your clinician.

Why vendor quality drives Hesperidin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Hesperidin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .